Xenetic biosciences, inc. presents positive preclinical data highlighting the potential of co-administration of dnase i with car t cells in a murine model of melanoma lung metastasis

Data presented at the aacr special conference in cancer research: tumor-body interactions: the roles of micro- and macroenvironment in cancer results bolster company's rationale for incorporating dnase i as an adjunctive treatment to improve therapeutic responses in patients undergoing car t cell therapy framingham, ma / accesswire / november 21, 2024 / xenetic biosciences, inc. (nasdaq:xbio) ("xenetic" or the "company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease i (dnase i) with chimeric antigen receptor (car) t cells in a syngeneic b16 melanoma murine model of lung metastasis. the poster titled, " the synergistic action of dnase i and car t cells enhances the therapeutic efficacy of adoptive immunotherapy in the syngeneic murine metastasis model ," was presented on behalf of the company by alexey stepanov, phd, institute investigator at the scripps research institute, at the aacr special conference in cancer research: tumor-body interactions: the roles of micro- and macroenvironment in cancer, held november 17-20, 2024, in boston.
CAR Ratings Summary
CAR Quant Ranking